WWW.JNEUROSCI.ORG
-
The Journal of Neuroscience
QUICK SEARCH:   [advanced]


     
-


HOME  |   SEARCH  |   ARCHIVE  |   SUBSCRIBE  |   CONTACT  |   HELP
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (116)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Villemagne, V.
Right arrow Articles by Ricaurte, G. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Villemagne, V.
Right arrow Articles by Ricaurte, G. A.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*COCAINE
*d-METHAMPHETAMINE
*DOPAMINE
*MAZINDOL
*TRITIUM
Medline Plus Health Information
*Drug Abuse
*Methamphetamine

 Previous Article  |  Next Article 

The Journal of Neuroscience, January 1, 1998, 18(1):419-427

Brain Dopamine Neurotoxicity in Baboons Treated with Doses of Methamphetamine Comparable to Those Recreationally Abused by Humans: Evidence from [11C]WIN-35,428 Positron Emission Tomography Studies and Direct In Vitro Determinations

Victor Villemagne1, Jie Yuan2, Dean F. Wong1, Robert F. Dannals1, George Hatzidimitriou2, William B. Mathews1, Hayden T. Ravert1, J. Musachio1, Una D. McCann3, and George A. Ricaurte2

1 Department of Radiology, Division of Nuclear Medicine and 2 Department of Neurology, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21205, and 3 Unit on Anxiety Disorders, Biological Psychiatry Branch, National Institute of Mental Health, Intramural Research Program, Bethesda, Maryland 20892

The present study sought to determine whether doses of methamphetamine in the range of those used recreationally by humans produce brain dopamine (DA) neurotoxicity in baboons and to ascertain whether positron emission tomography (PET) imaging with the DA transporter (DAT) ligand [11C]WIN-35,428 ([11C]2beta -carbomethoxy-3beta -(4-fluorophenyl)-tropane) could be used to detect methamphetamine-induced DAT loss in living primates. Baboons were treated with saline (n = 3) or one of three doses of methamphetamine [0.5 mg/kg (n = 2); 1 mg/kg (n = 2); and 2 mg/kg (n = 3)], each of which was given intramuscularly four times at 2 hr intervals. PET studies were performed before and 2-3 weeks after methamphetamine treatment. After the final PET studies, animals were killed for direct neurochemical determination of brain DA axonal markers. PET-derived binding potential values, used to index striatal DAT density, were significantly decreased after methamphetamine, with larger decreases occurring after higher methamphetamine doses. Reductions in striatal DAT documented by PET were associated with decreases in DA, dihydroxyphenylacetic acid, and specific [3H]WIN-35,428 and [3H]DTBZ binding determined in vitro. Decreases in DAT detected with PET were highly correlated with decreases in specific [3H]WIN-35,428 binding determined in vitro in the caudate of the same animal (r = 0.77; p = 0.042). These results indicate that methamphetamine, at doses used by some humans, produces long-term reductions in brain DA axonal markers in baboons, and that it is possible to detect methamphetamine-induced DAT loss in living nonhuman primates by means of PET.

Key words: methamphetamine; dopamine; neurotoxicity; PET; primates; WIN-35,428

Copyright © 1998 Society for Neuroscience  0270-6474/98/181419-09$05.00/0


This article has been cited by other articles:


Home page
 J Atten DisordHome page
C. Advokat
Literature Review: Update on Amphetamine Neurotoxicity and Its Relevance to the Treatment of ADHD
J Atten Disord, July 1, 2007; 11(1): 8 - 16.
[Abstract] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
J. Yuan, G. Hatzidimitriou, P. Suthar, M. Mueller, U. McCann, and G. Ricaurte
Relationship between Temperature, Dopaminergic Neurotoxicity, and Plasma Drug Concentrations in Methamphetamine-Treated Squirrel Monkeys
J. Pharmacol. Exp. Ther., March 1, 2006; 316(3): 1210 - 1218.
[Abstract] [Full Text] [PDF]

Home page
 Arch Gen PsychiatryHome page
Y. Sekine, Y. Ouchi, N. Takei, E. Yoshikawa, K. Nakamura, M. Futatsubashi, H. Okada, Y. Minabe, K. Suzuki, Y. Iwata, et al.
Brain Serotonin Transporter Density and Aggression in Abstinent Methamphetamine Abusers
Arch Gen Psychiatry, January 1, 2006; 63(1): 90 - 100.
[Abstract] [Full Text] [PDF]

Home page
 Arch Gen PsychiatryHome page
T. E. Nordahl, R. Salo, Y. Natsuaki, G. P. Galloway, C. Waters, C. D. Moore, S. Kile, and M. H. Buonocore
Methamphetamine Users in Sustained Abstinence: A Proton Magnetic Resonance Spectroscopy Study
Arch Gen Psychiatry, April 1, 2005; 62(4): 444 - 452.
[Abstract] [Full Text] [PDF]

Home page
 Arch Gen PsychiatryHome page
E. D. London, S. L. Simon, S. M. Berman, M. A. Mandelkern, A. M. Lichtman, J. Bramen, A. K. Shinn, K. Miotto, J. Learn, Y. Dong, et al.
Mood Disturbances and Regional Cerebral Metabolic Abnormalities in Recently Abstinent Methamphetamine Abusers
Arch Gen Psychiatry, January 1, 2004; 61(1): 73 - 84.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
J. L. CADET, S. JAYANTHI, and X. DENG
Speed kills: cellular and molecular bases of methamphetamine-induced nerve terminal degeneration and neuronal apoptosis
FASEB J, October 1, 2003; 17(13): 1775 - 1788.
[Abstract] [Full Text] [PDF]

Home page
 J. Neuropsychiatry Clin. Neurosi.Home page
A. D. Kalechstein, T. F. Newton, and M. Green
Methamphetamine Dependence Is Associated With Neurocognitive Impairment in the Initial Phases of Abstinence
J Neuropsychiatry Clin Neurosci, May 1, 2003; 15(2): 215 - 220.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. H. Baumann, M. A. Ayestas, L. G. Sharpe, D. B. Lewis, K. C. Rice, and R. B. Rothman
Persistent Antagonism of Methamphetamine-Induced Dopamine Release in Rats Pretreated with GBR12909 Decanoate
J. Pharmacol. Exp. Ther., June 1, 2002; 301(3): 1190 - 1197.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
J. P. Hansen, E. L. Riddle, V. Sandoval, J. M. Brown, J. W. Gibb, G. R. Hanson, and A. E. Fleckenstein
Methylenedioxymethamphetamine Decreases Plasmalemmal and Vesicular Dopamine Transport: Mechanisms and Implications for Neurotoxicity
J. Pharmacol. Exp. Ther., March 1, 2002; 300(3): 1093 - 1100.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Neuroradiol.Home page
L. Reneman, C. B. L. M. Majoie, H. Flick, and G. J. den Heeten
Reduced N-Acetylaspartate Levels in the Frontal Cortex of 3,4-Methylenedioxymethamphetamine (Ecstasy) Users: Preliminary Results
AJNR Am. J. Neuroradiol., February 1, 2002; 23(2): 231 - 237.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. PsychiatryHome page
Y. Sekine, M. Iyo, Y. Ouchi, T. Matsunaga, H. Tsukada, H. Okada, E. Yoshikawa, M. Futatsubashi, N. Takei, and N. Mori
Methamphetamine-Related Psychiatric Symptoms and Reduced Brain Dopamine Transporters Studied With PET
Am J Psychiatry, August 1, 2001; 158(8): 1206 - 1214.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
B. Ladenheim, I. N. Krasnova, X. Deng, J. M. Oyler, A. Polettini, T. H. Moran, M. A. Huestis, and J. L. Cadet
Methamphetamine-Induced Neurotoxicity Is Attenuated in Transgenic Mice with a Null Mutation for Interleukin-6
Mol. Pharmacol., April 13, 2001; 58(6): 1247 - 1256.
[Abstract] [Full Text]

Home page
 BrainHome page
Y. Ouchi, T. Kanno, H. Okada, E. Yoshikawa, M. Futatsubashi, S. Nobezawa, T. Torizuka, and K. Tanaka
Changes in dopamine availability in the nigrostriatal and mesocortical dopaminergic systems by gait in Parkinson's disease
Brain, April 1, 2001; 124(4): 784 - 792.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. PsychiatryHome page
N. D. Volkow, L. Chang, G.-J. Wang, J. S. Fowler, M. Leonido-Yee, D. Franceschi, M. J. Sedler, S. J. Gatley, R. Hitzemann, Y.-S. Ding, et al.
Association of Dopamine Transporter Reduction With Psychomotor Impairment in Methamphetamine Abusers
Am J Psychiatry, March 1, 2001; 158(3): 377 - 382.
[Abstract] [Full Text]

Home page
 J. Neurosci.Home page
T. Xie, U. D. McCann, S. Kim, J. Yuan, and G. A. Ricaurte
Effect of Temperature on Dopamine Transporter Function and Intracellular Accumulation of Methamphetamine: Implications for Methamphetamine-Induced Dopaminergic Neurotoxicity
J. Neurosci., October 15, 2000; 20(20): 7838 - 7845.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
S. Kim, R. Westphalen, B. Callahan, G. Hatzidimitriou, J. Yuan, and G. A. Ricaurte
Toward Development of an In Vitro Model of Methamphetamine-Induced Dopamine Nerve Terminal Toxicity
J. Pharmacol. Exp. Ther., May 1, 2000; 293(2): 625 - 633.
[Abstract] [Full Text]

Home page
 J PsychopharmacolHome page
M. R. Basso and R. A. Bornstein
Neurobehavioural consequences of substance abuse and HIV infection
J Psychopharmacol, May 1, 2000; 14(3): 228 - 237.
[Abstract] [PDF]

Home page
 J. Neurosci.Home page
X. Deng, B. Ladenheim, L.-I Tsao, and J. L. Cadet
Null Mutation of c-fos Causes Exacerbation of Methamphetamine-Induced Neurotoxicity
J. Neurosci., November 15, 1999; 19(22): 10107 - 10115.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
U. D. McCann, D. F. Wong, F. Yokoi, V. Villemagne, R. F. Dannals, and G. A. Ricaurte
Reduced Striatal Dopamine Transporter Density in Abstinent Methamphetamine and Methcathinone Users: Evidence from Positron Emission Tomography Studies with [11C]WIN-35,428
J. Neurosci., October 15, 1998; 18(20): 8417 - 8422.
[Abstract] [Full Text] [PDF]


-
-

Home  |   Search  |   Archive  |   Subscribe  |   Contact  |   Help
-
Copyright 2009 by Society for Neuroscience ONLINE ISSN: 1529-2401
-